Genetic polymorphisms of paraoxonase1 192 and glutathione peroxidase1 197 enzymes in familial Mediterranean fever

F. Öktem1, H. Anıl2, R. Sütcü3 and A.E. Kuybul2

1Department of Pediatric Nephrology, School of Medicine, Bezmialem Vakif University, Istanbul, Turkey
2Department of Pediatric Nephrology, School of Medicine, Suleyman Demirel University, Isparta, Turkey
3Department of Biochemistry and Clinical Biochemistry, School of Medicine, İzmir Katip Celebi University, İzmir, Turkey

Corresponding author: F. Öktem
E-mail: oktemfaruk@hotmail.com

Received February 5, 2013
Accepted September 13, 2013
Published April 29, 2014
DOI http://dx.doi.org/10.4238/2014.April.29.7

ABSTRACT. Familial Mediterranean fever (FMF) is an autosomal recessive disorder and is the most frequent of the periodic febrile inflammatory syndromes. The pathogenesis of the disease is not completely understood, even though the FMF gene has been identified. Oxidative stress and inflammation may play a role in the pathogenesis of FMF. We investigated gene polymorphisms of the antioxidative enzymes, glutathione peroxidase (GPX) and paraoxonase (PON) in FMF patients, and possible associations with FMF pathogenesis. Sixty FMF patients during an attack-free period and 51 healthy children as the control group were included in our study. PON1 Q/R192 and GPX1 Pro197Leu gene polymorphisms were assayed. Blood urea nitrogen, creatinine and serum lipid profile were also measured. PON1 Q/R192 genotype distribution was 52% QQ, 46% QR and 2% RR in the FMF group and 45% QQ, 45% QR and 10% RR in the control group (P >
0.05). GPX1 Pro197Leu genotype distribution was 28% PP, 57% PL, 15% LL in the FMF group and 18% PP, 53% PL, 29% LL in the control group (P > 0.05). Blood urea nitrogen, serum creatinine, lipid levels, and the distribution of PON1 Q/R192 and GPX1 Pro197Leu genotypes were similar in the two groups. We conclude that the PON1 Q/R192 and GPX1 Pro197Leu gene polymorphisms are not important risk factors in the development of FMF. However, larger studies are warranted to validate these conclusions.

Key words: Familial Mediterranean fever; Inflammation; Paraoxonase; Oxidative stress; Glutathione peroxidase; Gene polymorphism

INTRODUCTION

Familial Mediterranean fever (FMF) is an autosomal recessive hereditary disease that is characterized by recurrent attacks of fever and peritonitis, pleuritis, arthritis, or erysipelas-like skin lesions (Livneh et al., 1997). The gene responsible for FMF is designated as Mediterranean fever gene (MEFV) and mapped to a small interval on the short arm of chromosome 16 (Centola et al., 2000). However, the exact pathogenesis of the acute episodes of FMF is still unknown. Many studies have been established to clarify the mechanism of the inflammatory attacks in FMF, but possible factors triggering these attacks have not yet been identified (Centola et al., 2000). Some of the latest studies have suggested that sustained inflammation and oxidative stress are present during attack-free periods, and this is important in the further understanding of the disease pathogenesis (Bagci et al., 2004). Increased oxidative stress has an important role in the development of various inflammatory reactions such as ischemia-reperfusion injury, metabolic diseases and pathological conditions (Ozguner et al., 2005; Hashemi et al., 2010; Oktem et al., 2011). Increased oxidative stress has been demonstrated in patients with FMF (Karaguezyan et al., 1996; Kirkali et al., 2008). An imbalance in oxidant and antioxidant mechanisms may influence cellular sensitivity to free radical damage and alter susceptibility to disease.

Human paraoxonase1 (PON1) is an antioxidant enzyme located on high density lipoprotein (Adkins et al., 1993; Hashemi et al., 2010). It has been associated with the detoxification of organophosphates and possibly in the prevention of low-density lipoprotein oxidation (Biasioli et al., 2003). Two major genetic polymorphisms of PON1 have been described due to glutamine or arginine at position 192 (Q/R192) and methionine or leucine at position 55 (L/M) (Uyar et al., 2011). These polymorphisms are associated with difference in serum activities and concentrations of the enzymes (Adkins et al., 1993). PON1 activity and polymorphisms have been found to be associated with several diseases including nephrological and rheumatological diseases such as chronic renal failure, focal segmental glomerulosclerosis, systemic lupus erythematosus, Behcet disease, rheumatoid arthritis, and Henoch-Schönlein purpura, as well as other diseases such as coronary artery disease, cerebral infarct, dementia, Alzheimer’s disease, type 2 diabetes mellitus, hyperthyroidism, and liver cirrhosis (Adkins et al., 1993; Kobayashi et al., 2002; Biasioli et al., 2003; Hashemi et al., 2010).

Human glutathione peroxidase (GPX) is an antioxidant enzyme that is expressed in blood vessels (Suzen et al., 2010). Its role is protection of cells against oxidative damage by reducing hydrogen peroxide and a wide range of organic peroxidases to $\text{H}_2\text{O}_2$ with reduced glutathione. The
cytosolic form of GPX1 is a selenium-dependent enzyme. This enzyme is encoded by the GPX1 gene, which is located on chromosome 3p21, and one of the major genetic polymorphisms of this gene has been described as a leucine or proline at position 197 (Jefferies et al., 2005). This polymorphism continues to be questioned in relation to many diseases. In the autoinflammatory disease groups and FMF, there are no data on the GPX1 Pro197Leu gene polymorphism. 

The aim of the present study was to compare the frequency of the PON1 Q/R192 and GPX1 Pro197Leu gene polymorphisms in Turkish children with FMF and healthy controls. To our knowledge, this is the first study to investigate these polymorphisms in FMF patients.

MATERIAL AND METHODS

The study was carried out at Suleyman Demirel University Medical Faculty between July 2008 and July 2010 prospectively. Children with a diagnosis of FMF (N = 60) being followed up in the pediatric nephrology clinic and healthy volunteers without the history of any chronic disease and whom we called control group (N = 51) were included in this study. The project was carried out with the approval of the medical human Ethics Committee of the Suleyman Demirel University Faculty of Medicine, and all participants and/or their parents gave informed consent. The patients or their parents received a standard questionnaire containing questions regarding the age at FMF diagnosis, family history, origin, treatment, and the duration between the onset of symptoms and diagnosis. All patients were from the Mediterranean area of Turkey. None of the study participants was obese, a passive smoker, or under any medications known to interfere with lipid metabolism.

Patients

The patient group consisted of 60 children (33 boys, 27 girls) with a mean age of 11.5 ± 4.4 years at the time of diagnosis. All patients with FMF met Tel Hashomer criteria of the disease (Livneh et al., 1997). All patients were included in the study during an attack-free period. For the present study, patients were classified into three groups according to mutations; M694V homozygotes (16 patients, 27%), compound heterozygotes (24 patients, 40%) and heterozygote mutations + a patient with no mutation (20 patients, 33%). The control group consisted of 28 boys and 23 girls with mean age of 7.7 ± 4.3 years, without any family history of FMF or other chronic diseases among first-degree relatives. Also, all patients were further classified according to their PON1 Q/R192 gene polymorphism, namely QQ, QR and RR genotypes, and GPX1 Pro197Leu gene polymorphism namely PP, PL and LL genotypes. Venous blood samples were drawn to determine complete blood count, erythrocyte sedimentation rate, blood urea nitrogen (BUN), creatinine (Cr), uric acid, C-reactive protein (CRP), and triglyceride, total cholesterol, low-density lipoprotein and high-density lipoprotein cholesterol. Measurements were made using standard spectrophotometric methods (autoanalyzer, Abbott Aeroset, USA) in the hospital clinical laboratory.

Genotyping method for the PON1 Q/R192 polymorphism

Genomic DNA was extracted from peripheral blood samples containing EDTA by the salting out method (Miller et al., 1988). Genotypes for PON1 192 were determined by poly-
merase chain reaction (PCR) and restriction enzyme digestion (Mackness et al., 1996). For the
192 polymorphism, sense primer 5'-TAT TGT TGC TGT GGG ACC TGAG-3' and antisense
primer 5'-GAC ATA CTT GCC ATC GGG TGA A-3', which encompass the 192 polymorphic
region of the human PON1 gene, were used. The PCR mixture contained 100 ng DNA tem-
plate, 0.5 μM of each primer, 1.5 mM MgCl₂, 200 μM dNTPs, and 1 U Taq DNA polymerase
(MBI Fermentas). After denaturizing the DNA for 5 min at 94°C, the reaction mixture was
subjected to 35 cycles of denaturation for 1 min at 95°C, 1 min annealing at 60°C and 1 min
extension at 57°C for the 192 genotype. The 199-bp PCR product was digested with 8 U BspI
restriction endonuclease (New England Biolabs) overnight at 55°C and the digested products
separated by electrophoresis on a 4% agarose gel and visualized using ethidium bromide. The
R genotype contains a unique BspI restriction site, which results in 135- and 64-bp products
and the Q genotype cannot be cut, allowing the PON1 Q/R192 genotype to be determined.

Genotyping method for the GPX1 Pro197Leu polymorphism

Genotypes for GPX1 Pro197Leu were determined by PCR and restriction enzyme
digestion. For the Pro197Leu polymorphism, sense primer 5'-TTA TGA CCG ACC CCA AGC
TCA-3' and antisense primer 5'-ACA GCA GCA CTG CAA CTG CC-3'. The PCR mixture
contained 100 ng DNA template, 20 pmol primer, 1.5 mM MgCl₂, 200 μM dNTPs, and 1 U
Taq DNA polymerase (MBI Fermentas). After denaturizing the DNA for 3 min at 94°C, the
reaction mixture was subjected to 35 cycles of denaturation for 30 s at 94°C, 1 min annealing
at 58°C and 1 min extension at 72°C for the Pro197Leu genotype.

Statistical analysis

Statistical analyses were performed using the SPSS version 15.0 for Windows (SPSS
Inc., Chicago, IL, USA). All data are reported as means ± standard deviation. The non-parametric
Mann-Whitney U-test was used to compare variables, including duration, age, WBC (white blood
cell count), CRP, erythrocyte sedimentation rate, BUN, Cr, and cholesterol levels. Genotype com-
parisons of different groups were made using the chi-square test and the Fisher exact test (for
cases with insufficient expected cell frequencies). Because of the small number of patients in
each genotype group, the data were pooled according to case control-study-dominant model. In
addition, estimated relative risk odds ratio (OR) and confidence interval (CI) were measured. QQ
genotype frequency was compared with QR+RR genotype frequency and PP genotype frequency
was compared with PL+LL genotype frequency. P < 0.05 was accepted as significant.

RESULTS

The demographic characteristics of the FMF patients and healthy controls are shown in
Table 1. WBC, hemoglobin, hematocrit, serum CRP, BUN, Cr, and lipid levels of each case were
in the normal range according to their ages. There were no significant differences between groups
for gender, age, hemoglobin, hematocrit, BUN, Cr, and serum lipid levels (Table 1). Nineteen
of FMF patients and one of control subjects had elevated erythrocyte sedimentation rates (≥15
mm/h) (31 vs 1.9%, P = 0.0001). There were no significant differences in acute phase reactants
considering CRP levels and WBC between the FMF and control groups. All of those included in
the patient group were free of attack for at least 6 months. The PON1 Q/R192 genotype frequencies for FMF and control groups are shown in Table 2. Children with FMF and the control group had similar PON1 Q/R192 genotype distribution (QQ: 52 vs 45%; QR: 46 vs 45%; RR: 2 vs 10%, respectively) (Table 2). The frequency of the QQ genotype in the FMF group was comparable with the control group (Table 2) (52 vs 45%, P > 0.05). No significant difference existed in Q/R allele distribution between the two groups (0.75/0.25 vs 0.68/0.32, respectively; P > 0.05). GPX1 Pro197Leu genotype frequencies and distribution in children with FMF and the control group are shown in Table 3. The most frequent GPX1 Pro197Leu genotype was PL (57%), followed by PP (28%) and LL (15%) in children with FMF. The gene frequency for GPX1 Pro197Leu polymorphisms in controls and FMF patients was not different. Also, there was no significant difference between FMF and control groups in P/L allele distribution (0.57 vs 0.44, respectively; P > 0.05). When subgroups carried the M694V homozygous mutation (N = 16) and if healthy control group were separately compared regarding the results of PON1 192 and GPX1 Pro197Leu genotype, no significant differences were found between the groups (respectively P > 0.05; OR: 0.9, 95% CI: 0.3-2.9 and P > 0.05; OR: 2.8, 95% CI: 0.8-9.7).

### Table 1. Clinical and biochemical characteristics of children with FMF and the control group.

<table>
<thead>
<tr>
<th>Variable</th>
<th>FMF group (N = 60)</th>
<th>Control group (N = 51)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boy/girl</td>
<td>33/27</td>
<td>28/23</td>
<td>NS**</td>
</tr>
<tr>
<td>Age (years)</td>
<td>11.5 ± 4.4</td>
<td>7.7 ± 4.3</td>
<td>NS*</td>
</tr>
<tr>
<td>Age at onset (years)</td>
<td>5.4 ± 3.9</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Age at diagnosis (years)</td>
<td>10.9 ± 9.0</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Duration between onset and diagnosis (years)</td>
<td>5.5 ± 8.1</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Hematocrit</td>
<td>39.01 ± 0.53</td>
<td>37.59 ± 0.57</td>
<td>NS*</td>
</tr>
<tr>
<td>Hemoglobin</td>
<td>13.38 ± 0.19</td>
<td>13.49 ± 0.19</td>
<td>NS*</td>
</tr>
<tr>
<td>White blood cell count (10^3)/µL</td>
<td>7.5 ± 2.4</td>
<td>7.5 ± 2.9</td>
<td>NS*</td>
</tr>
<tr>
<td>C-reactive protein (mg/L)</td>
<td>4.4 ± 5.4</td>
<td>4.2 ± 3.3</td>
<td>NS*</td>
</tr>
<tr>
<td>Erythrocyte sedimentation rate (mm/h)</td>
<td>10.2 ± 11.2</td>
<td>5.8 ± 3.6</td>
<td>0.001*</td>
</tr>
<tr>
<td>Blood urea nitrogen (mg/dL)</td>
<td>11.0 ± 2.8</td>
<td>10.1 ± 3.0</td>
<td>NS*</td>
</tr>
<tr>
<td>Serum creatinine (mg/dL)</td>
<td>0.6 ± 0.1</td>
<td>0.5 ± 0.1</td>
<td>NS*</td>
</tr>
<tr>
<td>Serum total cholesterol (mg/dL)</td>
<td>148.9 ± 27.4</td>
<td>147.8 ± 30.7</td>
<td>NS*</td>
</tr>
<tr>
<td>Serum HDL cholesterol (mg/dL)</td>
<td>42.2 ± 10.3</td>
<td>46.6 ± 16.8</td>
<td>NS*</td>
</tr>
<tr>
<td>Serum LDL cholesterol (mg/dL)</td>
<td>84.3 ± 21.3</td>
<td>81.6 ± 27.0</td>
<td>NS*</td>
</tr>
<tr>
<td>Serum triglyceride (mg/dL)</td>
<td>106.7 ± 56.4</td>
<td>91.0 ± 41.7</td>
<td>NS*</td>
</tr>
</tbody>
</table>

Variables are reported as means ± standard deviation. FMF = familial Mediterranean fever. *Mann–Whitney U-test; **Chi-square test; NS = not significant.

### Table 2. Distribution of the PON1 Q/R192 gene polymorphism and allele frequencies in patients with FMF and the control group.

<table>
<thead>
<tr>
<th>PON1 192 genotypes [N (%)]</th>
<th>Alleles [N (%)]</th>
</tr>
</thead>
<tbody>
<tr>
<td>QQ QR RR</td>
<td>Q R</td>
</tr>
<tr>
<td>FMF (N = 60)</td>
<td>31 (52) 28 (46) 1 (2)</td>
</tr>
<tr>
<td>M694V homozygote (N = 16)</td>
<td>7 (44) 8 (50) 1 (6)</td>
</tr>
<tr>
<td>Compound heterozygote (N = 24)</td>
<td>14 (58) 10 (42) 0 (0)</td>
</tr>
<tr>
<td>Heterozygote and no mutation (N = 20)</td>
<td>10 (50) 10 (50) 0 (0)</td>
</tr>
<tr>
<td>Control (N = 51)</td>
<td>23 (45) 23 (45) 5 (10)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>QQ QR RR</th>
<th>Q R</th>
</tr>
</thead>
<tbody>
<tr>
<td>OR</td>
<td>1.301 0.768</td>
</tr>
<tr>
<td>95%CI</td>
<td>0.616-2.751 0.363-1.625</td>
</tr>
<tr>
<td>P</td>
<td>NS NS</td>
</tr>
</tbody>
</table>

PON = paraoxonase; FMF = familial Mediterranean fever; OR = odds ratio; CI = confidence interval. *Chi square or Fisher exact test (pooled data QQ vs QR+RR); NS = not significant.
DISCUSSION

It is already known that specific MEFV mutations are not the only determinants of the phenotype in FMF but also unknown environmental factors or possible modifying genes that could act as triggers in this disease. Potential modifying genes that may be involved in disease pathogenesis are oxidative stress genes. Associations between oxidative stress and FMF were previously studied and it was found that even in attack-free periods, patients were subject to a subclinical inflammation, an upregulation of neutrophils and oxidative burst (Bagci et al., 2004; Kirkali et al., 2008). Slightly elevated erythrocyte sedimentation rates in our patients also showed that continuous subclinical inflammation is present in FMF patients even when free of attack for at least 6 months and in the absence of mild anemia.

Although measurement of CRP is well established to be the sensitive and active indicator of acute-phase response in FMF patients, we found similar CRP results in the two groups. CRP levels increase following an inflammatory condition within a short time and decrease rapidly. Therefore, in this study CRP results of patients may have been similar as in the control group.

During fever attacks, there is activation of acute phase reactions that result in neutrophilia and increase in serum amyloid A. Substantial influx of polymorphonuclear leukocytes into the affected tissues has also been observed (Tunca et al., 1999). Activated neutrophils generate reactive oxygen species including free radicals such as the highly reactive hydroxyl radical, which could cause oxidative damage (Ozguner et al., 2005; Kirkali et al., 2008). A few studies have shown that there is persistent subclinical inflammation present in FMF patients even when free of attack for at least 6 months and in the absence of mild anemia. Although measurement of CRP is well established to be the sensitive and active indicator of acute-phase response in FMF patients, we found similar CRP results in the two groups. CRP levels increase following an inflammatory condition within a short time and decrease rapidly. Therefore, in this study CRP results of patients may have been similar as in the control group.

During fever attacks, there is activation of acute phase reactions that result in neutrophilia and increase in serum amyloid A. Substantial influx of polymorphonuclear leukocytes into the affected tissues has also been observed (Tunca et al., 1999). Activated neutrophils generate reactive oxygen species including free radicals such as the highly reactive hydroxyl radical, which could cause oxidative damage (Ozguner et al., 2005; Kirkali et al., 2008). A few studies have shown that there is persistent subclinical inflammation present in FMF patients even when free of attack for at least 6 months and in the absence of mild anemia. Although measurement of CRP is well established to be the sensitive and active indicator of acute-phase response in FMF patients, we found similar CRP results in the two groups. CRP levels increase following an inflammatory condition within a short time and decrease rapidly. Therefore, in this study CRP results of patients may have been similar as in the control group.

In studies evaluating the effect of PON1 192 genotyping on lipid levels, it has been reported that the PON1 192 gene polymorphism is not a major inhibitor in the oxidation of low-density lipoprotein, and for this reason, it may not affect lipid levels (Kafadar et al., 2006; Kucukali et al., 2008). In the present study, there was no significant difference in serum lipid

Table 3. Distribution of the GPX1 Pro197Leu gene polymorphism and allele frequencies in patients with FMF and the control group.

<table>
<thead>
<tr>
<th>GPX1 Pro197Leu genotypes N (%)</th>
<th>Alleles N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PP</td>
<td>PL</td>
</tr>
<tr>
<td>FMF (N = 60)</td>
<td></td>
</tr>
<tr>
<td>17 (28)</td>
<td>34 (57)</td>
</tr>
<tr>
<td>MeH694V homozygote (N = 16)</td>
<td>6 (37)</td>
</tr>
<tr>
<td>Compound heterozygote (N = 24)</td>
<td>7 (29)</td>
</tr>
<tr>
<td>Heterozygote and no mutation (N = 20)</td>
<td>4 (20)</td>
</tr>
<tr>
<td>Control (N = 51)</td>
<td>9 (18)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PP</th>
<th>PL-LL</th>
<th>P</th>
<th>L</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.548</td>
<td>0.542</td>
<td>1.656</td>
<td>0.604</td>
</tr>
<tr>
<td>0.740-4.597</td>
<td>0.218-1.351</td>
<td>0.973-2.82</td>
<td>0.355-1.029</td>
</tr>
</tbody>
</table>

GPX = glutathione peroxidase; FMF = familial Mediterranean fever; OR = odds ratio; CI = confidence interval. *Chi square or Fisher exact test (pooled data PP versus PL+LL); NS = not significant.
levels between the patients with FMF and the control group. Genotype distribution for the PON1 192 polymorphism of the control group in the present study was similar to the data obtained for the control groups of previously reported studies (Van Himbergen et al., 2004; Kafadar et al., 2006; Kucukali et al., 2008). However, we did not find any significant difference between the FMF group and the control group regarding PON1 192 polymorphism in terms of both QQ and QR+RR genotypes and the frequency of Q and R alleles. To our knowledge, this is the first study to investigate the association between the PON1 192 polymorphism and FMF. Therefore, we can speculate that PON1 192 genotypes were not associated with FMF, and that PON1 192 Q allele or QQ genotype is not a risk factor for patients with FMF. However, the results of the present study should certainly be confirmed by further studies, and other PON1 polymorphisms should be studied as well.

Inflammation, oxidative stress and free radicals are important in the pathogenesis of FMF. Although, the relationship between oxidative stress and FMF has been discussed in various studies, the association between antioxidant enzyme gene polymorphisms including GPX1 Pro197Leu and FMF has not been evaluated in any study to date. We hypothesized in the present study that a polymorphism in the sequence of an important antioxidant enzyme, GPX1, may influence the biological behavior of this enzyme and therefore the clinical diversity of FMF. However, the present study did not reveal any statistically significant correlation between the Pro197Leu polymorphism of the GPX1 gene and FMF. Our findings suggest that GPX1 Pro197Leu is not associated with the physiopathology and frequency of FMF. There are limited studies about the GPX1 Pro197Leu polymorphism in the literature (Hansen et al., 2005; Shinkai et al., 2004, 2006; Wei et al., 2011). These studies conducted on the GPX1 Pro197Leu polymorphism mostly include malignancies; however, results concerning the relationship between malignancies and the GPX1 Pro197Leu polymorphism are contradictory. In studies conducted on a group of diseases such as colorectal carcinoma, prostatic carcinoma, schizophrenia, and tardive dyskinesia, it has been stated that the GPX1 Pro197Leu polymorphism is not a major risk factor for these diseases (Hansen et al., 2005; Shinkai et al., 2004, 2006; Choi et al., 2007).

It was shown that the GPX1 Leu allele was less responsive than the Pro allele during stimulation of the GPX1 enzyme activity by selenium supplementation in vitro (Uyar et al., 2011; Wei et al., 2011). The presence of a more frequent Pro allele may make FMF patients more vulnerable to oxidative stress. However, in the present study, there was no significant increase in frequencies of PP or P allele of the GPX1 Pro197Leu gene when compared with the control group.

Genetic variations in other defense genes may be important modifiers in the relationship of GPX1 with FMF. Thus, other antioxidant enzymes such as manganese superoxide dismutase (MnSOD), catalase, and glutathione-S-transferase, as well as oxidant enzymes such as xanthine oxidase and myeloperoxidase as candidates for oxidant/antioxidant imbalance in FMF should be taken into account in future studies. Analyses in conjunction with other reactive oxygen species-related polymorphisms will help to fully elucidate the contribution of these genes to FMF. For a greater understanding of the pathogenesis of FMF, larger studies are needed to evaluate whether any variant of the GPX1 gene contributes to the disease. A basic understanding about the expression and regulation of antioxidant enzymes in FMF is necessary to develop therapeutic interventions to control oxidative stress. Also, further investigations are warranted in larger populations with other antioxidant enzymes including GPX3 and GPX4, MnSOD, and glutathione-S-transferases, as the underlying cause of FMF.
There were some limitations of the present study to be considered. The activities or levels of PON and GPX enzymes were not measured, which may be considered important. However, PON and GPX enzyme activities are extremely unstable and affected by various environmental stimulations. Still, the determination of gene polymorphism frequencies confirmed the vulnerability of patients to oxidative stress in case of a stimulus. The present study was conducted with a relatively small number of patients. Larger studies evaluating PON1 192 and GPX1 Pro197Leu polymorphisms together with PON and GPX enzyme activity measurements in patients with FMF may be a guide to obtain more accurate results.

In conclusion, we did not find a relationship between FMF and PON1 192 and GPX1 Pro197Leu gene polymorphisms. Further studies with a large number of cases should be conducted to evaluate the role of these gene polymorphisms as well as other oxidative stress gene polymorphisms for understanding the pathogenesis of FMF. Furthermore, there is a need to include other ethnicities and nationalities to confirm our findings, and to fully examine the possible relationship between antioxidant enzyme gene polymorphisms and FMF.

REFERENCES


